Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients

Leukemia Research

Volumn 38, Issue 7, 2014, Pages 850-856

  Musialik, Ewa ^a   Bujko, Mateusz ^a   Kober, Paulina ^a   Grygorowicz, Monika Anna ^a   Libura, Marta ^b   Przestrzelska, Marta ^b   Juszczyński, Przemysław ^c   Borg, Katarzyna ^c   Florek, Izabela ^d   Jakóbczyk, Małgorzata ^d   Baranowska, Alicja ^e   Siedlecki, Janusz Aleksander ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Neuroortopedic Department Marian Weiss Memorial Mazowia Rehabilitation Center   (Poland)

Author keywords

Acute myelogenous leukemia; CCAAT enhancer binding protein; CEBPA; CEBPD; CEBPE; CEBPZ(DDIT3); DNA methylation; Gene expression

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN DELTA; CCAAT ENHANCER BINDING PROTEIN EPSILON;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ARTICLE; BONE MARROW; CEBPA GENE; CEBPD GENE; CEBPE GENE; CEBPZ GENE; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; FEMALE; GENDER; GENE; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ACUTE MYELOGENOUS LEUKEMIA; CCAAT/ENHANCER BINDING PROTEIN; CEBPA; CEBPD; CEBPE; CEBPZ(DDIT3); DNA METHYLATION; GENE EXPRESSION;

ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEINS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TRANSLOCATION, GENETIC;

EID: 84902106418     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.04.013     Document Type: Article

References (31)

1. Vardiman J., Hyjek E. World Health Organization, classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program 2008, 2011:250-256. (introduction: WHO classification of MPN variants).
2. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
3. Nakajima H. Role of transcription factors in differentiation and reprogramming of hematopoietic cells. Keio J Med 2011, 60:47-55.
4. Jost E., do O.N., Wilop S., Herman J.G., Osieka R., Galm O. Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. Leuk Res 2009, 33:443-449.
5. Griffiths E.A., Gore S.D., Hooker C.M., Mohammad H.P., McDevitt M.A., Smith B.D., et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010, 5:590-600.
6. Hollink I.H.I.M., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T.C.J., Zimmermann M., Peeters J.K., Valk P.J.M., et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011, 96:384-392.
7. Santana-Lemos B.A., de Lima Lange A.P.A., de Lira Benício M.T., José T.D.D.S., Lucena-Araújo A.R., Krause A., et al. The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica 2011, 96:617-620.
8. Lin T.-C., Hou H., Chou W.-C., Ou D.-L., Yu S.-L., Tien H.-F., et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 2011, 25:32-40.
9. Lin T.-C., Jiang S-S., Chou W.-C., Hou H.-A., Lin Y.-M., Chang C.-L., et al. Rapid assessment of the heterogeneous methylation status of CEBPA in patients with acute myeloid leukemia by using high-resolution melting profile. J Mol Diagn 2011, 13:514-519.
10. Szankasi P., Ho A.K., Bahler D.W., Efimova O., Kelley T.W. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features. Leuk Res 2011, 35:200-207.
11. Hackanson B., Bennett K.L., Brena R.M., Jiang J., Claus R., Chen S.-S., et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008, 68:3142-3151.
12. Chim C.S., Wong A.S.Y., Hospital Q.M. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 2002, 119:988-990.
13. Lu Y., Chen W., Chen W., Stein A., Weiss L.M., Huang Q. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics. Am J Hematol 2010, 85:426-430.
14. Fasan A., Alpermann T., Haferlach C., Grossmann V., Roller A., Kohlmann A., et al. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases. PLoS ONE 2013, 8:e54365.
15. Agrawal S., Hofmann W-K., Tidow N., Ehrich M., van den Boom D., Koschmieder S., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007, 109:3895-3905.
16. Negrotto S., Ng K.P., Jankowska A.M., Bodo J., Gopalan B., Guinta K., et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2011, 244-254.
17. Yao D.-M., Qian J., Lin J., Wang Y.-L., Chen Q., Qian Z., et al. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia. Leuk Res 2011, 35:957-960.
18. Walker H., Smith F.J., Betts D.R. Cytogenetics in acute myeloid leukaemia. Blood Rev 1994, 8:30-36.
19. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
20. Hoogenkamp M., Lichtinger M., Krysinska H., Lancrin C., Clarke D., Williamson A., et al. Early chromatin unfolding by RUNX1: a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program. Blood 2009, 114:299-309.
21. Mrózek K., Marcucci G., Nicolet D., Maharry K.S., Becker H., Whitman S.P., et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012, 30:4515-4523.
22. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
23. Guibal F.C., Alberich-Jorda M., Hirai H., Ebralidze A., Levantini E., Di Ruscio A., et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009, 114:5415-5425.
24. Kassem N., Fahmy A.E.-G., Desoky M., Medhat N., Zawam H.M. CCAAT/enhancer binding protein α gene expression in Egyptian patients with acute myeloid leukemia. J Egypt Natl Canc Inst 2013, 25:115-120.
25. Pabst T., Mueller B.U., Harakawa N., Schoch C., Haferlach T., Behre G., et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001, 7:444-451.
26. Cilloni D., Carturan S., Gottardi E., Messa F., Messa E., Fava M., et al. Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. Blood 2003, 102:2705-2706.
27. D'Alò F., Di Ruscio A., Guidi F., Fabiani E., Greco M., Rumi C., et al. PU.1 and CEBPA expression in acute myeloid leukemia. Leuk Res 2008, 32:1448-1453.
28. Helbling D., Mueller B.U., Timchenko N.A., Schardt J., Eyer M., Betts D.R., et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 2005, 106:1369-1375.
29. Wouters B.J., Jordà M.A., Keeshan K., Louwers I., Erpelinck-Verschueren C.A.J., Tielemans D., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007, 110:3706-3714.
30. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., Meijer J., van Oosterhoud S., van Putten W.L.J., Valk P.J.M., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003, 4:31-40.
31. Whitman S.P., Maharry K., Radmacher M.D., Becker H., Mrózek K., Margeson D., et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:3622-3626.